Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis

Dumoulin, Daphne W; Gietema, Hester A.; Paats, Marthe S.; Hendriks, Lizza; Cornelissen, Robin

doi:10.3389/fonc.2020.577696

Cited by 18 publications

(26 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, whilst ICI-associated pneumonitis may exacerbate pulmonary inflammation, COVID-19 infection may mask the symptoms of lungs’ immune-related adverse events, potentially postponing essential treatment [ 31 ]. The exact differential diagnosis would become crucial for providing the most appropriate treatment, and a multidisciplinary approach based on laboratory, radiographical, and pathological parameters may be helpful in discriminating between these two clinical entities [ 32 ]. Lastly, physicians should answer the challenging question of whether interactions are possible between treatments for COVID-19 and anticancer agents [ 33 ].…”

Section: Covid-19 and Immune Checkpoint Inhibitors: Different Considerationsmentioning

confidence: 99%

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Burgaletto

Brunetti

Munafò

et al. 2021

Cancers

View full text Add to dashboard Cite

Since the start of the global spread of coronavirus disease (COVID-19) pandemic, cancer patients were identified as a specifically susceptible subgroup of the patient population. Several reports have shown that cancer patients have an increased risk of both contracting the infection and of experiencing a more severe disease course, with a rapidly evolving picture associated with higher mortality. The assumption of cancer patients as “COVID-19 vulnerable” has led, irretrievably, to profound changes in the decision making of oncological treatments. Potential justifications for such concerns encompass the cancer-dependent suppression of the immune response, as well as the influence of administration of systemic anticancer treatments, including chemotherapy and immunotherapy. Nevertheless, to date, it is not clear whether the use of immune checkpoint inhibitors (ICIs) in cancer patients is safe, given their modulating effects on the immune system, or that they may rather conceal detrimental consequences. Theoretically, on the one hand, ICIs may enhance the immunological control of viral infections through their immunostimulating mechanisms; on the other hand, they could contribute to the hyper-inflammatory phase of COVID-19, worsening its clinical outcomes. In this study, we report the foremost clinical observations on the safety of ICI administration in cancer patients affected by COVID-19.

show abstract

Section: Covid-19 and Immune Checkpoint Inhibitors: Different Considerationsmentioning

confidence: 99%

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Burgaletto

Brunetti

Munafò

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…For curative treatment of bronchogenic carcinoma, factors to be taken into consideration include the risk of contracting COVID-19, adverse effects related to treatment, and availability of resources. Systemic therapies with shorter treatment course and reduced risk of myelosuppression are recommended[ 65 ].…”

Section: Guiding Principles For Treatment Of Patients With Bronchogenic Carcinomamentioning

confidence: 99%

Imaging diagnosis of bronchogenic carcinoma (the forgotten disease) during times of COVID-19 pandemic: Current and future perspectives

Ravikanth¹

2021

WJCO

View full text Add to dashboard Cite

Patients with bronchogenic carcinoma comprise a high-risk group for coronavirus disease 2019 (COVID-19), pneumonia and related complications. Symptoms of COVID-19 related pulmonary syndrome may be similar to deteriorating symptoms encountered during bronchogenic carcinoma progression. These resemblances add further complexity for imaging assessment of bronchogenic carcinoma. Similarities between clinical and imaging findings can pose a major challenge to clinicians in distinguishing COVID-19 super-infection from evolving bronchogenic carcinoma, as the above-mentioned entities require very different therapeutic approaches. However, the goal of bronchogenic carcinoma management during the pandemic is to minimize the risk of exposing patients to COVID-19, whilst still managing all life-threatening events related to bronchogenic carcinoma. The current pandemic has forced all healthcare stakeholders to prioritize per value resources and reorganize therapeutic strategies for timely management of patients with COVID-19 related pulmonary syndrome. Processing of radiographic and computed tomography images by means of artificial intelligence techniques can facilitate triage of patients. Modified and newer therapeutic strategies for patients with bronchogenic carcinoma have been adopted by oncologists around the world for providing uncompromised care within the accepted standards and new guidelines.

show abstract

“…In the early stage of COVID-19 patients, peripheral blood leukocytes were normal or decreased, lymphocyte count decreased, CRP and ESR increased in most patients, D-dimer and liver enzymes, LDH, muscle enzymes, myoglobin, and troponin increased in severe patients (Kattan et al, 2020;Wu et al, 2020). Besides, further bronchoscopy is needed if necessary (Dumoulin et al, 2020).…”

Section: Cancer Patients Receiving Immunotherapymentioning

confidence: 99%

Management and Thinking on the Treatment of Cancer Patients During the COVID-19

Pan

Jiang

Chen

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) has spread rapidly around the world and has become a public health emergency of international concern. The weekly epidemiological report issued by the WHO pointed out that new coronavirus variants have appeared in 131 countries and regions, which demonstrates that the current epidemic situation is still severe. As of now, the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been widespread worldwide for more than one year and poses a serious threat to the health of vulnerable groups such as those with malignancies, the elderly, and the immunocompromised. Compared with the general population, cancer patients with COVID-19 infection are more likely to have serious clinical adverse events, leading to higher mortality. There is no doubt that during the COVID-19 epidemic, whether it is with regards to how to prevent infection or how to continue anti-tumor treatment, cancer patients are in a difficult situation. Meanwhile, an international patient with malignant Hodgkin’s lymphoma who was cured after being infected with the new coronavirus surprised us, and it inspires more scientists to explore the relationship between infection, immunity, and tumors. Relevantly, through multi-disciplinary discussion, scientists put forward more new perspectives on the treatment of future tumors and the management of SARS-CoV-2 diseases. In this review, the impact of COVID-19 on cancer patients is discussed in detail and the recommendations for the diagnosis, treatment and management of cancer patients will be put forward under the challenge of the COVID-19 epidemic. Furthermore, the safety and effectiveness of the SARS-CoV-2 vaccine will be discussed, and we will also put forward our insights on cancer immunity.

show abstract

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis

Cited by 18 publications

References 60 publications

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era

Imaging diagnosis of bronchogenic carcinoma (the forgotten disease) during times of COVID-19 pandemic: Current and future perspectives

Management and Thinking on the Treatment of Cancer Patients During the COVID-19

Contact Info

Product

Resources

About